Site icon pharmaceutical daily

Circulating Tumor Cell (CTC) Diagnostics Technologies and Global Markets Report 2022 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Circulating Tumor Cell (CTC) Diagnostics: Technologies and Global Markets” report has been added to ResearchAndMarkets.com’s offering.

The scope of this study involves clinical testing, prognostic and monitoring markets for CTCs in cancer. The report also includes the clinical research segment as well as currently approved CTC tests and their markets.

By cancer type, the global market for circulating tumor cells diagnostics has been segmented into breast cancer, colorectal cancer and prostate cancer. The fast growth rate of the colorectal cancer segment is attributed to rapid rise in the incidence of colorectal cancer, especially young adults.

The growing prevalence of cancer, as circulating tumor cells find their applications in the diagnosis of cancer and precision management; advancements in technologies such as NGS and immunofluorescence; and growing awareness about the novel diagnostic methods for cancers are all major factors that will boost market growth.

Reasons for Doing this Study

This study was conducted to provide detailed information regarding new developments, prognostic and clinical research testing for circulating tumor cells. There is an increasing need for new and innovative technologies in this area. This industry is experiencing tremendous growth; the use of new prognostic technologies based on circulating tumor cells has increased in the past few years.

This study will increase awareness of current and emerging technologies and practices for cancer and cancer research, especially for prostate, breast and colorectal cancers.

The regulatory environment, current technologies, new technologies, cancer incidence, market projections and market share, along with the latest trends and new developments in this area, are included to support the clinical testing market.

This report discusses some of the major drivers and restraints in the market for circulating tumor cells diagnostics, and it surveys the competitive landscape as well as the key players’ strategies and performances. The discussion is focused on the major market players, trends in product launches, collaborations, and mergers and acquisitions.

The report also includes company profiles of major vendors that include a company overview, key product offerings, financial statistics and recent developments. The report provides insights on market shares and upcoming regional demand for circulating tumor cells diagnostics.

Some of the major market players discussed in the report are Qiagen N.V., Biocept Inc., Greiner Bio One International GmbH, Precision Medicine Group LLC and Menarini Silicon Biosystems.

For market estimates, data have been provided for the 2020 as the base year, with forecasts for 2021 through 2026. Projected and forecasted revenue values are in constant U.S. dollars that have not been adjusted for inflation.

Report Includes

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

Chapter 4 CTC Diagnostic Technologies

Chapter 5 Impact of Covid-19 on the CTC Diagnostics Market

Chapter 6 Market Dynamics

Chapter 7 Market Breakdown by Cancer Type

Chapter 8 Market Breakdown by Technology

Chapter 9 Market Breakdown by Application

Chapter 10 Market Breakdown by Region

Chapter 11 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/jugnfg

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version